- Home
- DSP vs NMRA Comparison
DSP vs NMRA Comparison
Compare DSP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- NMRA
- Stock Information
- Founded
- DSP 1999
- NMRA 2019
- Country
- DSP United States
- NMRA United States
- Employees
- DSP N/A
- NMRA N/A
- Industry
- DSP EDP Services
- NMRA
- Sector
- DSP Technology
- NMRA
- Exchange
- DSP Nasdaq
- NMRA Nasdaq
- Market Cap
- DSP 291.3M
- NMRA 287.6M
- IPO Year
- DSP 2021
- NMRA 2023
- Fundamental
- Price
- DSP $21.01
- NMRA $1.80
- Analyst Decision
- DSP Strong Buy
- NMRA Strong Buy
- Analyst Count
- DSP 6
- NMRA 6
- Target Price
- DSP $20.67
- NMRA $20.67
- AVG Volume (30 Days)
- DSP 328.0K
- NMRA 2.0M
- Earning Date
- DSP 03-03-2025
- NMRA 03-06-2025
- Dividend Yield
- DSP N/A
- NMRA N/A
- EPS Growth
- DSP N/A
- NMRA N/A
- EPS
- DSP 0.08
- NMRA N/A
- Revenue
- DSP $263,587,000.00
- NMRA N/A
- Revenue This Year
- DSP $28.28
- NMRA N/A
- Revenue Next Year
- DSP $12.68
- NMRA N/A
- P/E Ratio
- DSP $276.27
- NMRA N/A
- Revenue Growth
- DSP 23.73
- NMRA N/A
- 52 Week Low
- DSP $7.77
- NMRA $1.60
- 52 Week High
- DSP $26.33
- NMRA $21.00
- Technical
- Relative Strength Index (RSI)
- DSP 44.34
- NMRA 27.76
- Support Level
- DSP $21.93
- NMRA $1.61
- Resistance Level
- DSP $26.33
- NMRA $1.80
- Average True Range (ATR)
- DSP 1.57
- NMRA 0.11
- MACD
- DSP -0.37
- NMRA 0.23
- Stochastic Oscillator
- DSP 2.21
- NMRA 51.28
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.